Use of recombinant human erythropoietin (r-HuEPO) in a Jehovah's Witness refusing transfusion of blood products: case report.
Recombinant human erythropoietin (r-HuEPO) administration to a Jehovah's witness refusing blood transfusions increased her nadir packed cell volume from 13% to 37% and reticulocyte count from 2% to 17.7%. R-HuEPO may provide an alternative safe and effective therapy in life-threatening anemia when blood transfusions are unacceptable to the patient.
Koestner
J A
JA
Department of Pharmaceutical Services, Vanderbilt University Hospital, Nashville, Tennessee 37232-7610.
Nelson
L D
LD
Morris
J A
JA
Safcsak
K
K
D000063:Accidents, Traffic; D000077:Acetabulum / Q000293:injuries*; D000328:Adult; D001803:Blood Transfusion; D002835:Christianity; D004305:Dose-Response Relationship, Drug; D004906:Erythrocyte Count; D004921:Erythropoietin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000150:complications* / Q000209:etiology; D006400:Hematocrit; D006801:Humans; D010384:Pelvic Bones / Q000293:injuries*; D012156:Reticulocytes; D012771:Shock, Hemorrhagic / Q000097:blood / Q000209:etiology / Q000628:therapy*; D016312:Treatment Refusal
D004921:Erythropoietin